Parthenon has achieved impressive results since its founding in 2019. We’ve built a pipeline of first-in-class therapeutics & a platform designed to generate a sustained cadence of novel therapeutics & have already enabled the discovery & development of therapies heading into the clinic in 2023.
BOSTON (PRWEB) October 12, 2022
Female Founders 100 recognition highlights Parthenon Co-Founder as an entrepreneur with a world-changing company
Parthenon Therapeutics today announced that its Co-Founder and Chief Operating Officer, Olga Granaturova, was named to Inc.'s fifth annual Female Founders 100 list, honoring women whose innovations and ideas are changing the world.
Parthenon is paving the way for a new generation of cancer treatments and has already enabled the discovery and development of first-in-class therapeutics. Founded by four people who believe cancer therapies should be developed differently, the company is addressing a reality that despite enormous advances, cancer treatments are effective only for a small population of patients. Parthenon’s novel class of anti-cancer therapies breaks down the protective barrier that surrounds cancer cells, creating a path for immune cells to infiltrate and kill tumors.
As a co-founder, Granaturova beat the odds to build a high-performance diverse scientific team including renowned scientific advisors who are united by a compelling purpose: to bend the survival curve for cancer patients. Her dedication to addressing meaningful gaps extends beyond health to inspire and support women in their entrepreneurial pursuits both within Parthenon and beyond. Granaturova also elevates and supports women-led startups through Brighter Ventures, an organization she co-founded to empower, educate and support female entrepreneurs.
Inc. editors reviewed thousands of applications highlighting female founders who are challenging the status quo and tackling some of the world’s biggest problems. The list features women who have overcome challenges and lifted those around them, while leading impactful organizations across the country.
“These 100 female founders have identified solutions to difficult problems and created valuable, industry-changing companies out of them. We congratulate this year’s list on their achievements and look forward to their continued success,” says Inc. editor-in-chief Scott Omelianuk.
“Parthenon Therapeutics has achieved impressive results since its founding in 2019. We’ve built a pipeline of first-in-class therapeutics and a platform designed to generate a sustained cadence of novel therapeutics over the long arc of the company and have already enabled the discovery and development of a first-in-class therapeutic heading into the clinic in 2023,” said Olga Granaturova. “But what I’m equally proud of is the inclusive culture we’ve built. That diversity is a key ingredient of our success.”
To see the recognition visit https://www.inc.com/profile/olga-granaturova or pick up the October 2022 issue on newsstands beginning October 4.
About Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information visit parthenontx.com and LinkedIn.
The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning, multiplatform content reaches more than 50 million people each month across a variety of channels, including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion among the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.